OCT3 polymorphisms and reduced hepatic OCT3 expression, caused by cholestasis and liver fibrosis, lead to reduced metformin uptake, thereby impacting its therapeutic action through changed pharmacokinetics7,16,17. This evidence concerns the gene SLC22A3 and cholestasis.